Pruritus in Primary Biliary Cirrhosis: Pathogenesis and Therapy

Clinics in Liver Disease

Volumn 12, Issue 2, 2008, Pages 385-406

  Bergasa, Nora V ^a  

^a WOODHULL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DRONABINOL; DROPERIDOL; FLUMECINOL; GABAPENTIN; HYDROXYZINE; LIDOCAINE; LIDOCAINE ETHOBROMIDE; METHOTREXATE; METRONIDAZOLE; MIRTAZAPINE; NALFURAFINE; NALOXONE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; PHENOBARBITAL; PLACEBO; PREDNISONE; PROPOFOL; RESIN; RIFAMPICIN; S ADENOSYLMETHIONINE; SERTRALINE; TACROLIMUS; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

BLOATING; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; DETOXIFICATION; DIALYSIS; DRY EYE; HUMAN; LIVER DISEASE; LOW DRUG DOSE; NEUROTRANSMISSION; NONHUMAN; OSTEOPENIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOTOTHERAPY; PINEAPPLE JUICE; PLASMAPHERESIS; PRIMARY BILIARY CIRRHOSIS; PRURITOGEN; PRURITUS; REVIEW; SENSATION; XEROSTOMIA;

HUMANS; LIVER CIRRHOSIS, BILIARY; PRURITUS;

EID: 43049123134     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.02.013     Document Type: Review

References (149)

1. Rishe E., Azarm A., and Bergasa N.V. Itch in primary biliary cirrhosis: a patients' perspective. Acta Derm Venereol 88 (2008) 34-37
2. Heathcote J. The clinical expression of primary biliary cirrhosis. Semin Liver Dis 17 (1997) 23-33
3. Wendel B., and Hoehe M.R. The human mu opioid receptor gene: 5' regulatory and intronic sequences. J Mol Med 76 (1998) 525-532
4. Hirota T., Ieiri I., Takane H., et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31 (2003) 677-680
5. Bond C., LaForge K.S., Tian M., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95 (1998) 9608-9613
6. Lin Xiang Wei, Floriani A, Variola A, et al. A Study of the mu opioid receptor gene polymorphism A 118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm Venereol 2008, in press.
7. Floreani A., Carderi I., Variola A., et al. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology 43 (2006) 1152-1154
8. Dietrich C.G., Geier A., and Oude Elferink R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 (2003) 1788-1795
9. Dombrowski S.M., Desai S.Y., Marroni M., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 (2001) 1501-1506
10. Keppler D., Leier I., and Jedlitschky G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378 (1997) 787-791
11. Hoffmaster K.A., Zamek-Gliszczynski M.J., Pollack G.M., et al. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metab Dispos 33 (2005) 287-293
12. Newton J.L., Bhala N., Burt J., et al. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol 44 (2006) 776-783
13. Shapiro J.M., Smith H., and Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20 (1979) 137-140
14. Talwalkar J.A., Souto E., Beigley C.S., et al. Natural history of pruritus in primary biliary cirrhosis. J Clinical Gastroenterol Hepatol 1 (2003) 297-302
15. Poupon R., Chazouilleres O., Balkau B., et al. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J Hepatol 30 (1999) 408-412
16. Lloyd-Thomas H.G., and Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. Br Med J 2 (1952) 1289-1291
17. Greaves M.W., and Wall P.D. Pathophysiology of itching. Lancet 348 (1996) 938-940
18. Talbot T.L., Schmitt J.M., Bergasa N.V., et al. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Technol 25 (1991) 400-403
19. Stein H., Bijak M., Heerd E., et al. [Pruritometer 1: portable measuring system for quantifying scratching as an objective measure of cholestatic pruritus]. Biomed Tech (Berl) 41 (1996) 248-252 [in German]
20. Molenaar H.A., Oosting J., and Jones E.A. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 36 (1998) 220-224
21. Bijak M., Mayr W., Rafolt D., et al. Pruritometer 2: portable recording system for the quantification of scratching as objective criterion for the pruritus. Biomed Tech (Berl) 46 (2001) 137-141
22. Reichen J., and Simon F. Cholestasis. In: Arias I.M., Jakoby W.B., Popper H., et al. (Eds). The liver: biology and pathobilogy. 2nd edition (1988), Raven Press, New York 1105-1124
23. Jones E.A., and Bergasa N.V. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology 11 (1990) 884-887
24. Thornton J.R., and Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ 297 (1988) 1501-1504
25. Bergasa N.V., Alling D.W., Talbot T.L., et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 41 (1999) 431-434
26. Bergasa N.V., Schmitt J.M., Talbot T.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27 (1998) 679-684
27. Bergasa N.V., Alling D.W., Talbot T.L., et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 123 (1995) 161-167
28. Bergasa N.V., Vergalla J., Swain M.G., et al. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 16 (1996) 298-302
29. Bergasa N. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 22 (2002) 107-113
30. Swain M.G., Rothman R.B., Xu H., et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 103 (1992) 630-635
31. Spivey J.R., Jorgensen R.A., Gores G.J., et al. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 89 (1994) 2028-2032
32. Bergasa N.V., Alling D.W., Vergalla J., et al. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 20 (1994) 85-90
33. Piercey M.F., Schroeder L.A., Folkers K., et al. Sensory and motor functions of spinal cord substance P. Science 214 (1981) 1361-1363
34. Kuraishi Y., Nagasawa T., Hayashi K., et al. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 275 (1995) 229-233
35. King T., Gardell L.R., Wang R., et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 116 (2005) 276-288
36. Ossipov M.H., Lai J., King T., et al. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers 80 (2005) 319-324
37. Trivedi M., Wei L.X., and Bergasa N.V. Serum concentrations of Substance P are increased in cholestasis: potential clinical implications. Gastroenterology (Supplement) 130 (2005)
38. Raderer M., Muller C., and Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 21 (1994) 1540
39. Schworer H., and Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 341 (1993) 1277
40. O'Donohue J.W., Haigh C., and Williams R. Ondansetron in the treatment of the pruritus of cholestasis: a randomised controlled trial. Gastroenterology 112 (1997) A1349
41. Jones E.A., Molenaar H.A., and Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 54 (2007) 1196-1199
42. O'Donohue J.W., Pereira S.P., Ashdown A.C., et al. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 21 (2005) 1041-1045
43. Muller C., Pongratz S., Pidlich J., et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 10 (1998) 865-870
44. Schworer H., Hartmann H., and Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5- hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 61 (1995) 33-37
45. Browning J., Combes B., and Mayo M.J. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 2736-2741
46. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 45 (2007) 666-674
47. Richardson B.P. Serotonin and nociception. Ann N Y Acad Sci 600 (1990) 511-520
48. Thomsen J.S., Petersen M.B., Benfeldt E., et al. Scratch induction in the rat by intradermal serotonin: a model for pruritus. Acta Derm Venereol 81 (2001) 250-254
49. Nojima H., and Carstens E. Quantitative assessment of directed hind limb scratching behavior as a rodent itch model. J Neurosci Methods 126 (2003) 137-143
50. Swain M.G., and Maric M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 25 (1997) 291-294
51. Celik T., Goren M.Z., Cinar K., et al. Fatigue of cholestasis and the serotoninergic neurotransmitter system in the rat. Hepatology 41 (2005) 731-737
52. LaMotte R.H. Subpopulations of "nocifensor neurons" contributing to pain and allodynia, itch and allokinesis. Am Pain Soc J 1 (1992) 115-126
53. Ikoma A., Fartasch M., Heyer G., et al. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology 62 (2004) 212-217
54. Schmelz M., Hilliges M., Schmidt R., et al. Active "itch fibers" in chronic pruritus. Neurology 61 (2003) 564-566
55. Andrew D., and Craig A.D. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 4 (2001) 72-77
56. Inan S., and Cowan A. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 85 (2006) 39-43
57. Ko M.C., Lee H., Song M.S., et al. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 305 (2003) 173-179
58. Ko M.C., Song M.S., Edwards T., et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 310 (2004) 169-176
59. Wikstrom B., Gellert R., Ladefoged S.D., et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16 (2005) 3742-3747
60. Sun Y.G., and Chen Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448 (2007) 700-703
61. Umeuchi H., Kawashima Y., Aoki C.A., et al. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride. Eur J Pharmacol 518 (2005) 133-139
62. Kirby J., Heaton K.W., and Burton J.L. Pruritic effect of bile salts. Br Med J 4 (1974) 693-695
63. Varadi D.P. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 109 (1974) 678-681
64. Ricci P., Hofmann A.F., Hagey L.R., et al. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig Dis Sci 43 (1998) 1292-1295
65. Hsieh J.C., Hagermark O., Stahle-Backdahl M., et al. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 72 (1994) 3004-3008
66. Mochizuki H., Tashiro M., Kano M., et al. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 105 (2003) 339-346
67. Drzezga A., Darsow U., Treede R.D., et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 92 (2001) 295-305
68. Darsow U., Drzezga A., Frisch M., et al. Processing of histamine-induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol 115 (2000) 1029-1033
69. Walter B., Sadlo M.N., Kupfer J., et al. Brain activation by histamine prick test-induced itch. J Invest Dermatol 125 (2005) 380-382
70. Leknes S.G., Bantick S., Willis C.M., et al. Itch and motivation to scratch: an investigation of the central and peripheral correlates of allergen- and histamine-induced itch in humans. J Neurophysiol 97 (2007) 415-422
71. Mochizuki H., Sadato N., Saito D.N., et al. Neural correlates of perceptual difference between itching and pain: a human fMRI study. Neuroimage 36 (2007) 706-717
72. Valet M., Pfab F., Sprenger T., et al. Cerebral processing of histamine-induced itch using short-term alternating temperature modulation-an fMRI study. J Invest Dermatol 128 (2008) 426-433
73. Bergasa N.V., Talbot T.L., Alling D.W., et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102 (1992) 544-549
74. Bergasa N.V., McGee M., Ginsburg I.H., et al. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology 44 (2006) 1317-1323
75. de la Fuente-Fernandez R., Ruth T.J., Sossi V., et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 (2001) 1164-1166
76. Horta M.L., Ramos L., and Goncalves Z.R. The inhibition of epidural morphine-induced pruritus by epidural droperidol. Anesth Analg 90 (2000) 638-641
77. Horta M.L., Ramos L., Goncalves Zda R., et al. Inhibition of epidural morphine-induced pruritus by intravenous droperidol. The effect of increasing the doses of morphine and of droperidol. Reg Anesth 21 (1996) 312-317
78. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. In: Molinoff P.B., and Ruddon R.W. (Eds). The pharmacological basis of therapeutics (1996), McGraw-Hill, New York 399-430
79. Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action?. Eur J Pharmacol 94 (1983) 341-344
80. Andrews N., Loomis S., Blake R., et al. Effect of gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology (Berl) 157 (2001) 381-387
81. Wager T.D., Rilling J.K., Smith E.E., et al. Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303 (2004) 1162-1167
82. Datta D.V., and Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 50 (1966) 323-332
83. Berg C. Use of colesevelam hydrochloride (Welchol) as a novel therapeutic agent for the management of refractory pruritus in chronic liver disease. Hepatology 34 (2001) 541
84. Pusl T., Denk G.U., Parhofer K.G., et al. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 45 (2006) 887-891
85. Acevedo Ribo M., Moreno Planas J.M., Sanz Moreno C., et al. Therapy of intractable pruritus with MARS. Transplant Proc 37 (2005) 1480-1481
86. Pares A., Cisneros L., Salmeron J.M., et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 99 (2004) 1105-1110
87. Doria C., Mandala L., Smith J., et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 9 (2003) 437-443
88. Sturm E., Franssen C.F., Gouw A., et al. Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver 22 Suppl 2 (2002) 72-75
89. Rifai K., Hafer C., Rosenau J., et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand J Gastroenterol 41 (2006) 1212-1217
90. Beuers U., Gerken G., and Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 44 (2006) 280-281
91. Bustorff-Silva J., Sbraggia Neto L., Olimpio H., et al. Partial internal biliary diversion through a cholecystojejunocolonic anastomosis-a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report. J Pediatr Surg 42 (2007) 1337-1340
92. Whitington P.F., and Whitington G.L. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 95 (1988) 130-136
93. Ng V.L., Ryckman F.C., Porta G., et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 30 (2000) 152-156
94. Bernstein J.E., and Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 115 (1979) 1366-1367
95. Carson K.L., Tran T.T., Cotton P., et al. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 91 (1996) 1022-1023
96. Wolfhagen F.H., Sternieri E., Hop W.C., et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 113 (1997) 1264-1269
97. Terg R., Coronel E., Sorda J., et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 37 (2002) 717-722
98. Mansour-Ghanaei F., Taheri A., Froutan H., et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 12 (2006) 1125-1128
99. McRae C.A., Prince M.I., Hudson M., et al. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 125 (2003) 591-596
100. Millan M.J., Czlonkowski A., Morris B., et al. Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain 35 (1988) 299-312
101. Perrot S., Guilbaud G., and Kayser V. Differential behavioral effects of peripheral and systemic morphine and naloxone in a rat model of repeated acute inflammation. Anesthesiology 94 (2001) 870-875
102. Willer J.C., Dehen H., and Cambier J. Stress-induced analgesia in humans: endogenous opioids and naloxone-reversible depression of pain reflexes. Science 212 (1981) 689-691
103. Reisine T. Pasternak: opioid analgesics and antagonists. In: Molinoff P.B., and Ruddon R.W. (Eds). The pharmacologic basis of therapeutics. 9th edition (1996), McGraw-Hill, New York 521-555
104. Yosipovitch G., and Stander S. Meeting report of the 3rd International Workshop for the Study of Itch. J Invest Dermatol 126 (2006) 1928-1930
105. Dawn A.G., and Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 54 (2006) 527-531
106. Stehling L.C., and Zauder H.L. Double-blind comparison of butorphanol tartrate and meperidine hydrochloride in balanced anaesthesia. J Int Med Res 6 (1978) 384-387
107. Fisher M.A., and Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 48 (1997) 1156-1160
108. Yu L. The mu opioid receptor: from molecular cloning to functional studies. Addict Biol 1 (1996) 19-30
109. Lewis J.W., and Husbands S.M. The orvinols and related opioids-high affinity ligands with diverse efficacy profiles. Curr Pharm Des 10 (2004) 717-732
110. Zylicz Z., and Krajnik M. Codeine for pruritus in primary biliary cirrhosis. Lancet 353 (1999) 813
111. Juby L.D., Wong V.S., and Losowsky M.S. Buprenorphine and hepatic pruritus. Br J Clin Pract 48 (1994) 331
112. Reddy L., Krajnik M., and Zylicz Z. Transdermal buprenorphine may be effective in the treatment of pruritus in primary biliary cirrhosis. J Pain Symptom Manage 34 (2007) 455-456
113. Diehn F., and Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 115 (2001) 619-621
114. Zylicz Z., Krajnik M., Sorge A.A., et al. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 26 (2003) 1105-1112
115. Zylicz Z., Smits C., and Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 16 (1998) 121-124
116. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand Suppl 391 (1997) 31-37
117. Davis P., Frandsen J.I., Walsh D., et al. Mirtazapine for pruritus. J Pain Symptom Manage 25 (2003) 288-291
118. Hundley J.L., and Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 50 (2004) 889-891
119. Hoensch H.P., Balzer K., Dylewizc P., et al. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 28 (1985) 475-477
120. Tirona R.G., Leake B.F., Wolkoff A.W., et al. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304 (2003) 223-228
121. Ghent C.N., and Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94 (1988) 488-493
122. Bachs L., Parés A., Elena M., et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102 (1992) 2077-2080
123. Prince M.I., Burt A.D., and Jones D.E. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50 (2002) 436-439
124. Heathcote E.J. Is rifampin a safe and effective treatment for pruritus caused by chronic cholestasis?. Nat Clin Pract Gastroenterol Hepatol 4 (2007) 200-201
125. Khurana S., and Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 26 (2006) 943-948
126. Berg C.L., and Gollan J.L. Primary biliary cirrhosis: new therapeutic directions. Scand J Gastroenterol Suppl 192 (1992) 43-49
127. Sherlock S., and Dooley J. Primary biliary cirrhosis. In: Sherlock S., and Dooley J. (Eds). Diseases of the liver and biliary system (1991), Blackwell, London 236-248
128. Turner I.B., Rawlins M.D., Wood P., et al. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 8 (1994) 337-342
129. Watson J.P., Jones D.E., James O.F., et al. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. J Gastroenterol Hepatol 14 (1999) 1034-1040
130. Bloomer J.R., and Boyer J.L. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 82 (1975) 310-317
131. Ghent C.N., Bloomer J.R., and Hsia Y.E. Efficacy and safety of long-term phenobarbital therapy of familial cholestasis. J Pediatr 93 (1978) 127-132
132. Bachs L., Parés A., Elena M., et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1 (1989) 574-576
133. Walt R., Daneshmend T., and Fellows I. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J (Clin Res Ed) 296 (1988) 607
134. Mitchison H.C., Bassendine M.F., Malcolm A.J., et al. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 10 (1989) 420-429
135. Aguilar-Bernier M., Bassas-Vila J., Sanz-Munoz C., et al. Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol 152 (2005) 808-809
136. Wallengren J., and Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres. Acta Derm Venereol 84 (2004) 111-115
137. Bergasa N.V., Link M.J., Keogh M., et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 96 (2001) 1563-1570
138. Frezza M., Surrenti C., Manzillo G., et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 99 (1990) 211-215
139. Frezza M., Centini G., Cammareri G., et al. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 139 Suppl 2 (1990) 122-125
140. Horsmans Y., and Geubel A.P. Pruritus associated with cholestatic liver disease. Ann Intern Med 125 (1996) 701
141. Neff G.W., O'Brien C.B., Reddy K.R., et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 97 (2002) 2117-2119
142. Watson W.C. Intravenous lignocaine for relief of intractable itch. Lancet 1 (1973) 211
143. Borgeat A., Wilder-Smith O.H., and Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 104 (1993) 244-247
144. Borgeat A., Wilder-Smith O., Saiah M., et al. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anesthesiology 76 (1992) 510-512
145. Borgeat A., Wilder-Smith O., Mentha G., et al. Propofol and cholestatic pruritus. Am J Gastroenterol 87 (1992) 672-674
146. Villamil A.G., Bandi J.C., Galdame O.A., et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med 118 (2005) 1160-1163
147. Kim B.M., Lee S.H., Shim W.S., et al. Histamine-induced Ca(2+) influx via the PLA(2)/lipoxygenase/TRPV1 pathway in rat sensory neurons. Neurosci Lett 361 (2004) 159-162
148. Shim W.S., Tak M.H., Lee M.H., et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 27 (2007) 2331-2337
149. Binshtok A.M., Bean B.P., and Woolf C.J. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature 449 (2007) 607-610